Great Point Partners’s Jade Biosciences JBIO Stock Holding History

Great Point Partners’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.6M	Buy	964,462 +158,189	+20%	+$2.29M	3.11%	13
2025 Q4	$12.4M	Buy	806,273 +173,674	+27%	+$2.04M	4.03%	10
2025 Q3	$5.46M	Buy	632,599 +134,545	+27%	+$1.1M	2.25%	16
2025 Q2	$4.98M	Buy	+498,054	New	+$17M	3.24%	12
2024 Q2	–	Sell	-25,363	Closed	-$26.2M	–	36
2024 Q1	$26.2M	Sell	25,363 -4,285	-14%	-$3.27M	4.09%	8
2023 Q4	$23.5M	Sell	29,648 -1,530	-5%	-$780K	4%	9
2023 Q3	$14.8M	Buy	31,178 +4,545	+17%	+$2.46M	2.7%	16
2023 Q2	$16M	Buy	26,633 +5,044	+23%	+$3.23M	3.13%	15
2023 Q1	$15.2M	Buy	21,589 +10,774	+100%	+$8.94M	2.99%	16
2022 Q4	$11.1M	Buy	+10,815	New	+$7.85M	2.17%	20

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Great Point Partners's JBIO Position: Q1 2026 in Review

Great Point Partners increased its Jade Biosciences (JBIO) stake by 20% in Q1 2026, buying an estimated $2.29M and bringing the position to 964,462 shares worth $13.6M. The position accounts for 3.11% of the portfolio, ranked #13.

Great Point Partners first reported a position in JBIO in Q4 2022 and has held it in 10 quarters since. The position peaked at $26.2M in Q1 2024. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

Great Point Partners held 964,462 shares of Jade Biosciences worth $13.6M as of Q1 2026.
Great Point Partners bought 158,189 Jade Biosciences shares in Q1 2026, an estimated $2.29M.
Jade Biosciences made up 3.11% of Great Point Partners's portfolio in Q1 2026, its #13 holding.
Great Point Partners first reported a position in Jade Biosciences in Q4 2022 and has held it in 10 quarters since.
Great Point Partners's Jade Biosciences position peaked at $26.2M in Q1 2024.
120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.